Author:
Urbaniak Anna,Jablonska Karolina,Suchanski Jaroslaw,Partynska Aleksandra,Szymczak-Kulus Katarzyna,Matkowski Rafal,Maciejczyk Adam,Ugorski Maciej,Dziegiel Piotr
Abstract
AbstractWe have previously shown that high expression of prolactin-induced protein (PIP) correlates with the response of breast cancer (BC) patients to standard adjuvant chemotherapy (doxorubicin and cyclophosphamide), which suggests that the absence of this glycoprotein is associated with resistance of tumor cells to chemotherapy. Therefore, in the present study, we analyzed the impact of PIP expression on resistance of BC cells to anti-cancer drugs and its biological role in BC progression. Expression of PIP and apoptotic genes in BC cell lines was analyzed using real-time PCR and Western blotting. PIP was detected in BC tissue specimens using immunohistochemistry. The tumorigenicity of cancer cells was analyzed by the in vivo tumor growth assay. Apoptotic cells were detected based on caspase-3 activation, Annexin V binding and TUNEL assay. The interaction of PIP with BC cells was analyzed using flow cytometry. Using two cellular models of BC (i.e. T47D cells with the knockdown of the PIP gene and MDA-MB-231 cells overexpressing PIP), we found that high expression of PIP resulted in (1) increased sensitivity of BC cells to apoptosis induced by doxorubicin (DOX), 4-hydroperoxycyclophosphamide (4-HC), and paclitaxel (PAX), and (2) improved efficacy of anti-cancer therapy with DOX in the xenograft mice model. Accordingly, a clinical study revealed that BC patients with higher PIP expression were characterized by longer 5-year overall survival and disease-free survival. Subsequent studies showed that PIP up-regulated the expression of the following pro-apoptotic genes: CRADD, DAPK1, FASLG, CD40 and BNIP2. This pro-apoptotic activity is mediated by secreted PIP and most probably involves the specific surface receptor. This study demonstrates that a high expression level of PIP sensitizes BC cells to anti-cancer drugs. Increased sensitivity to chemotherapy is the result of pro-apoptotic activity of PIP, which is evidenced by up-regulation of specific pro-apoptotic genes. As high expression of PIP significantly correlated with a better response of patients to anti-cancer drugs, this glycoprotein can be a marker for the prognostic evaluation of adjuvant chemotherapy.
Funder
Law on Higher Education and Science
Narodowe Centrum Nauki
Publisher
Springer Science and Business Media LLC
Reference78 articles.
1. Haagensen, D. E., Dilley, W. G., Mazoujian, G. & Wells, S. A. Review of GCDFP-15 an apocrine marker protein. Ann. N. Y. Acad. Sci. 586, 161–173 (1990).
2. Mazoujian, G., Pinkus, G. S., Davis, S. & Haagensen, D. E. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast: A marker of apocrine epithelium and breast carcinomas with apocrine features. Am. J. Pathol. 110, 105 (1983).
3. Schenkels, L. C. P. M., Rathman, W. M., Veerman, E. C. I. & Amerongen, A. V. N. Detection of proteins related to a salivary glycoprotein (EP-GP): Concentrations in human secretions (saliva, sweat, tears, nasal mucus, cerumen, seminal plasma). Biol. Chem. Hoppe Seyler. 372, 325–330 (1991).
4. Schaller, J. et al. Primary structure of a new actin-binding protein from human seminal plasma. Eur. J. Biochem. 196, 743–750 (1991).
5. Schenkels, L. C. P. M., Veerman, E. C. I. & NieuwAmerongen, A. V. EP-GP and the lipocalin VEGh, two different human salivary 20-kDa proteins. J. Dent. Res. 74, 1543–1550 (1995).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献